Pantokaltsin

General characteristics. Structure:

Active agent: calcium гопантенат (gopantenovy acid or calcic salt of gopantenovy acid) 0,25 g (250 mg) ; 0,5 g (500 mg)

Excipients: magnesium a hydroxycarbonate — 46,77/93,54 mg; calcium stearate — 3,1/6,2 mg; talc — 6,2/12,4 mg; potato starch — 3,93/7,86 mg.

Pharmacological properties:

Pharmacodynamics. The action spectrum is connected with existence in structure of GAMK. The mechanism of action is caused by a direct impact of the drug Pantokaltsin® on a GAMKB-retseptor-kanalny complex. Has neurometabolic, neuroprotective and neurotrophic properties. Increases resistance of a brain to a hypoxia and influence of toxic substances, stimulates anabolic processes in neurons. Possesses anticonvulsant action, reduces motor excitability with simultaneous streamlining of behavior. Increases intellectual and physical effeciency. Contributes to normalization of maintenance of GAMK at a chronic drunkenness and the subsequent cancellation of ethanol. Shows analgeziruyushchy action. It is capable to inhibit the acetylation reactions participating in mechanisms of an inactivation of novocaine and streptocides thanks to what prolongation of action of the last is reached. Causes braking patholologically of the raised vesical reflex and a tone of a detruzor.

Pharmacokinetics. At intake it is quickly soaked up from a GIT. Tmax in a blood plasma makes 1 h. The greatest concentration are created in a liver, kidneys, a stomach wall, skin. Gets through GEB. It is not metabolized and removed in not changed look during 48 h (67,5% of the accepted dose — with urine, 28,5% — with a stake).

Indications to use:

- cognitive disturbances at organic lesions of a brain and neurotic frustration;
- as a part of complex therapy of the cerebrovascular insufficiency caused by atherosclerotic changes of vessels of a brain; senile dementia (an initial form), residual organic lesions of a brain at persons of mature age and elderly;
cerebral organic insufficiency at patients with schizophrenia (in a combination with neuroleptics, antidepressants);
- extrapyramidal hyperkinesias at patients with hereditary diseases of a nervous system (including a chorea of Gentington, hepatocerebral dystrophy, Parkinson's disease);
effects of the postponed neuroinfections and craniocereberal injuries (as a part of complex therapy);
- correction and prevention (therapy of cover at co-administration) side effect of neuroleptics; extrapyramidal antipsychotic syndrome (hyperkinetic and akinetic);
- epilepsy with delay of mental processes (in a combination with anticonvulsant drugs);
- psychoemotional overloads, decrease in intellectual and physical effeciency; for improvement of concentration of attention and storing;
- frustration of an urination: enuresis, day incontience of urine, pollakiuria, imperative desires;

Children:
- mental retardation (delay of mental, speech, motor development or their combination);
- cerebral palsy;
- stutter (preferential clonic form);
- epilepsy (as a part of a combination therapy with anticonvulsant drugs, especially at polymorphic attacks and small epileptic seizures).

Route of administration and doses:

Inside.
To accept in 15–30 min. after food.

The single dose for adults makes 0,5–1 g, for children — 0,25–0,5 g, daily — 1,5–3 g (for adults), 0,75–3 g (for children). Duration of a course of treatment — from 1 to 4 month, in some cases — up to 6 months. In 3–6 months carrying out a repeated course of treatment is possible.
Children. Intellectual insufficiency — on 0,5 g of 4-6 times a day, daily within 3 months. A delay of speech development — on 0,5 g 3–4 times a day within 2–3 months.
Antipsychotic syndrome (as the proofreader of side effect of neuroleptics). Adults — on 0,5–1 g 3 times a day; children — 0,25–0,5 g 3–4 times a day. Duration of a course of treatment — 1–3 months.
Epilepsy. Children — on 0,25–0,5 g 3–4 times a day; adults — on 0,5–1 g 3–4 times a day daily for a long time (up to 6 months).
Hyperkinesias (tics). Children — on 0,25–0,5 g of 3-6 times a day daily within 1–4 months; adults — on 1,5–3 g a day daily within 1–5 months.
Frustration of an urination. Adults — on 0,5–1 g 2–3 times a day (a daily dose — 2–3 g); children — on 0,25–0,5 g (a daily dose — 25–50 mg/kg). Duration of a course of treatment — of 2 weeks up to 3 months (depends on expressiveness of frustration and therapeutic effect).
Effects of neuroinfections and craniocereberal injuries. 0,25 g 3–4 times a day.
For maintenance at the raised loadings and asthenic states. 0,25 g 3 times a day.
This dosage form is not recommended to children up to 3 years.

Features of use:

This dosage form of drug is not recommended to children under 3 years.

Side effects:

Allergic reactions (rhinitis, conjunctivitis, skin rashes) are possible.

Interaction with other medicines:

Prolongs action of barbiturates; strengthens effects of the drugs stimulating TsNS, anticonvulsant HP, effect of local anesthetics (Procainum). Prevents side effect of the following HP: phenobarbital, carbamazepine, antipsychotic means (neuroleptics).

Effect of gopantenovy acid amplifies in combination with glycine, a xydibackground.

Contraindications:

- hypersensitivity;
- acute renal failure;
- pregnancy (I trimester).

Use at pregnancy and feeding by a breast
Contraindicated in the I trimester of pregnancy.

Overdose:

Data on overdose of the drug Pantokaltsin® are not provided.

Storage conditions:

In the dry, protected from light place, at a temperature not above 25 °C.
To store in the place, unavailable to children.

Issue conditions:

According to the recipe

Packaging:

Tablets, 250 mg, 500 mg. In blister strip packagings from a film of PVC and aluminum foil on 10 pieces. In banks polymeric complete with covers on 50 pieces. In a pack of cardboard 5 packagings or 1 bank.